» Articles » PMID: 17637610

ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia

Overview
Date 2007 Jul 20
PMID 17637610
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

In elderly persons, antipsychotic drugs are clinically prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications (schizophrenia and bipolar disorder). The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia. In April 2005, the FDA, based on a meta-analysis of 17 double-blind randomized placebo-controlled trials among elderly people with dementia, determined that atypical antipsychotics were associated with a significantly (1.6-1.7 times) greater mortality risk compared with placebo, and asked that drug manufacturers add a 'black box' warning to prescribing information for these drugs. Most deaths were due to either cardiac or infectious causes, the two most common immediate causes of death in dementia in general. Clinicians, patients, and caregivers are left with unclear choices of treatment for dementia patients with psychosis and/or severe agitation. Not only are psychosis and agitation common in persons with dementia but they also frequently cause considerable caregiver distress and hasten institutionalization of patients. At the same time, there is a paucity of evidence-based treatment alternatives to antipsychotics for this population. Thus, there is insufficient evidence to suggest that psychotropics other than antipsychotics represent an overall effective and safe, let alone better, treatment choice for psychosis or agitation in dementia; currently no such treatment has been approved by the FDA for these symptoms. Similarly, the data on the efficacy of specific psychosocial treatments in patients with dementia are limited and inconclusive. The goal of this White Paper is to review relevant issues and make clinical and research recommendations regarding the treatment of elderly dementia patients with psychosis and/or agitation. The role of shared decision making and caution in using pharmacotherapy for these patients is stressed.

Citing Articles

Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study.

Mok P, Carr M, Guthrie B, Morales D, Sheikh A, Elliott R BMJ. 2024; 385:e076268.

PMID: 38631737 PMC: 11022137. DOI: 10.1136/bmj-2023-076268.


Sexually Dimorphic Effects of Neuromodulatory Drugs on Normal and Stress-Induced Social Interaction in Rats.

Ishaq S, Ahmed T Brain Sci. 2023; 13(10).

PMID: 37891747 PMC: 10604924. DOI: 10.3390/brainsci13101378.


Interaction of amisulpride with GLUT1 at the blood-brain barrier. Relevance to Alzheimer's disease.

Boyanova S, Lloyd-Morris E, Corpe C, Rahman K, Farag D, Page L PLoS One. 2023; 18(10):e0286278.

PMID: 37874822 PMC: 10597500. DOI: 10.1371/journal.pone.0286278.


Acute Antipsychotic Use and Presence of Dysphagia Among Older Veterans with Heart Failure.

Robison R, Singh M, Jiang L, Riester M, Duprey M, McGeary J J Am Med Dir Assoc. 2023; 24(9):1303-1310.

PMID: 37478895 PMC: 10527768. DOI: 10.1016/j.jamda.2023.06.009.


Searching for new drugs for the treatment of dementia-related psychosis.

Zakrzewska-Sito A, Kuczynska J Postep Psychiatr Neurol. 2023; 30(4):270-277.

PMID: 37082556 PMC: 9881640. DOI: 10.5114/ppn.2021.111942.


References
1.
Katz I, Jeste D, E Mintzer J, Clyde C, Napolitano J, Brecher M . Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999; 60(2):107-15. DOI: 10.4088/jcp.v60n0207. View

2.
Jeste D, Lacro J, Bailey A, Rockwell E, Harris M, Caligiuri M . Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999; 47(6):716-9. DOI: 10.1111/j.1532-5415.1999.tb01595.x. View

3.
De Deyn P, Rabheru K, Rasmussen A, Bocksberger J, Dautzenberg P, Eriksson S . A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999; 53(5):946-55. DOI: 10.1212/wnl.53.5.946. View

4.
Jeste D, Finkel S . Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000; 8(1):29-34. DOI: 10.1097/00019442-200002000-00004. View

5.
Glazer W . Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000; 61 Suppl 3:16-21. View